✦ LIBER ✦

Maximally tolerated dose of the muscarinic agonist CI-979 in Alzheimer's disease (AD)

✍ Scribed by N.R. Cutler; J.J. Sramek; R.D. Seifert; J. Hourani; P.A. Reece; H. Bockbrader; A.J. Sedman; T.S. Wardle

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and tolerability of CI-979 in pat

✍ John J. Sramek; Allen J. Sedman; Phillip A. Reece; Jameel Hourani; Howard Bockbr 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 677 KB

Preclinical and Phase 1 clinical charact

✍ Allen J. Sedman; Howard Bockbrader; Roy D. Schwarz 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 445 KB

S.28.04 Muscarinic agonists in the treat

✍ Raj Kumar 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 297 KB

Muscarinic agonists and antagonists in t

✍ W Greenlee; J Clader; T Asberom; S McCombie; J Ford; H Guzik; J Kozlowski; S Li; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 206 KB

The utility of muscarinic agonists in th

✍ William S. Messer 📂 Article 📅 2002 🏛 Humana Press Inc 🌐 English ⚖ 98 KB

Antagonism of scopolamine-induced memory

✍ M. M'Harzi; A.-M. Palou; C. Oberlander; F. Barzaghi 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 641 KB